Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 56,400 shares, a growth of 32.4% from the August 15th total of 42,600 shares. Based on an average trading volume of 29,900 shares, the short-interest ratio is presently 1.9 days.
Bioasis Technologies Stock Performance
BIOAF remained flat at $0.13 during midday trading on Friday. The firm's fifty day moving average is $0.12 and its 200 day moving average is $0.16. Bioasis Technologies has a 52-week low of $0.10 and a 52-week high of $0.28.
Get
Bioasis Technologies alerts:
About Bioasis Technologies
(Get Rating)
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 56,400 shares, a growth of 32.4% from the August 15th total of 42,600 shares. Based on an average trading volume of 29,900 shares, the short-interest ratio is presently 1.9 days.
生物綠洲科技公司(BiOASIS Technologies Inc.)是8月份空頭股數大幅增長的目標。截至8月31日，空頭股數共有56,400股，較8月15日的42,600股增長32.4%。以平均成交量29,900股計算，目前短息比率為1.9天。
Bioasis Technologies Stock Performance
BIOAF remained flat at $0.13 during midday trading on Friday. The firm's fifty day moving average is $0.12 and its 200 day moving average is $0.16. Bioasis Technologies has a 52-week low of $0.10 and a 52-week high of $0.28.
週五午盤，BIOAF持平於0.13美元。該公司的50日移動均線切入位為0.12美元，200日移動均線切入位為0.16美元。BiOasis Technologies的52周低點為0.10美元，52周高位為0.28美元。
Get
Bioasis Technologies
alerts:
About Bioasis Technologies
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技術公司是一家處於發展階段的生物製藥公司，致力於神經疾病和障礙的診斷和治療產品的研究和開發。它正在開發xB3，這是一種通過血腦屏障(BBB)運輸治療劑的平臺技術；以及治療中樞神經系統疾病(CNS)，包括腦癌，以及代謝和神經退行性疾病。
Featured Stories
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- 免費獲取StockNews.com關於BiOASIS技術的研究報告(BIOAF)
- 第四季度值得考慮的3家銀行
- 股市：紅海中的三座強國
- MarketBeat：回顧一週9/12-9/16
- 沒有人告訴這三隻股票這是下跌的一週
- 有什麼辦法可以治癒Teladoc股票的問題嗎？
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BiOasis Technologies及相關公司的評級的每日摘要。
